Telix Pharmaceuticals Limited vs Ionis Pharmaceuticals, Inc.: Examining Key Revenue Metrics

Biotech Revenue Battle: Ionis vs. Telix from 2014-2023

__timestampIonis Pharmaceuticals, Inc.Telix Pharmaceuticals Limited
Wednesday, January 1, 201421416100028336824
Thursday, January 1, 201528370300032319194
Friday, January 1, 201634662000029404631
Sunday, January 1, 201750766600031769230
Monday, January 1, 201859967400020439380
Tuesday, January 1, 2019112300000024186536
Wednesday, January 1, 20207290000004680000
Friday, January 1, 20218100000004898000
Saturday, January 1, 2022587000000155984000
Sunday, January 1, 2023787647000496659000
Monday, January 1, 2024705138000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Biotech Giants: Revenue Trends from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market influence. Over the past decade, Ionis Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited have showcased contrasting revenue trajectories. Ionis Pharmaceuticals, a leader in RNA-targeted therapeutics, has seen its revenue grow by approximately 268% from 2014 to 2023, peaking in 2019. This growth underscores its robust pipeline and strategic partnerships. Meanwhile, Telix Pharmaceuticals, specializing in radiopharmaceuticals, experienced a staggering 1,650% increase in revenue over the same period, with a significant surge in 2022 and 2023. This remarkable growth reflects its successful product launches and expanding market presence. As these companies continue to innovate, their revenue trends offer valuable insights into the evolving landscape of the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025